Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

BACKGROUND: COVID-19 poses a global health challenge with more than 325 million cumulative cases and above 5 million cumulative deaths reported till January 17, 2022, by the World Health Organization. Several potential treatments to treat COVID-19 are under clinical trials including antivirals, ster...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Shaukat, Shalim, Elisha, Farhan, Farah, Anjum, Fatima, Ali, Ayesha, Uddin, Syed Muneeb, Shahab, Faisal, Haider, Mustafa, Ahmed, Iqra, Ali, Mir Rashid, Khan, Sadaf, Rao, Sadia, Guriro, Kabeer, Elahi, Saud, Ali, Muhammad, Mushtaq, Tehreem, Sayeed, Muneeba Ahsan, Muhaymin, Sheikh Muhammad, Luxmi, Shoba, Saifullah, Qureshi, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643954/
https://www.ncbi.nlm.nih.gov/pubmed/36348476
http://dx.doi.org/10.1186/s13063-022-06860-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643954/
https://www.ncbi.nlm.nih.gov/pubmed/36348476
http://dx.doi.org/10.1186/s13063-022-06860-2

Ejemplares similares